Johnson & Johnson (JNJ) Offering Possible 16.28% Return Over the Next 10 Calendar Days

This article was originally published on this site

Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $130.00 short put and a strike $125.00 long put offers a potential 16.28% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $130.00 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock dropped below the $125.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 70.12 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs
Sun, 05 Aug 2018 23:42:02 +0000
NANJING, China—At a cancer conference in Chicago in June last year, a little-known Chinese startup stunned researchers with early results showing its experimental gene therapy was abating an aggressive form of blood cancer in patients back home. Six months later, the startup, Nanjing Legend Biotechnology Co., received $350 million from Johnson & Johnson for the global rights to co-develop and market the experimental treatment. In May, the U.S. Food and Drug Administration approved its testing on Americans, making it the first Chinese-developed gene therapy to receive such a signoff.

The 4 Cheapest ‘Dividend Kings’ to Buy Today
Sat, 04 Aug 2018 16:00:00 +0000
In the world of investing, Dividend Kings are the best of the best when it comes to returning cash to shareholders over the long term. You can see the full list of Dividend Kings here. In this article, we’ll explore four Dividend Kings that are trading with the largest discounts to fair value today.

Eli Lilly’s Q2 2018 Earnings: New Products
Fri, 03 Aug 2018 11:31:00 +0000
Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.

Missouri governments sue drug companies over opioid epidemic
Thu, 02 Aug 2018 20:13:39 +0000
Ten Missouri counties and one city filed suit Wednesday against 49 companies, accusing them of worsening the opioid epidemic by misbranding drugs, among other things. The 274-page lawsuit, filed in St. Louis Circuit Court, seeks damages on behalf of the plaintiffs and their residents. The plaintiffs are Jefferson, Cape Girardeau, Christian, Crawford, Greene, Iron, Jasper, Stone, Taney, and Washington counties, and the city of Joplin.

WHO sees complex vaccine and security questions in Ebola response
Thu, 02 Aug 2018 18:06:32 +0000
It will be complicated and perhaps impossible to use a vaccine to tackle Democratic Republic of Congo’s new Ebola outbreak, the World Health Organization’s emergency response chief said on Thursday. An Ebola outbreak was declared in northeastern Congo’s North Kivu province on Wednesday, and almost 20 WHO officials are already on their way to the epicentre, Peter Salama told Reuters at WHO’s headquarters in Geneva. Officials have not yet confirmed which type of Ebola is causing the outbreak.

Be Sociable, Share!

Related Posts